NXTC News and Press, NextCure Inc. From 03/23/24

2024-03-23 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for som...

2024-03-21 11:30:31 ET More on NextCure Seeking Alpha’s Quant Rating on NextCure Historical earnings data for NextCure Financial information for NextCure Read the full article on Seeking Alpha For further details see: NextCure GAAP EPS of -...

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC) Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts with data updates in 2024 LNCB74, in collaboration with LegoChem, planned filing...

X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...

AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...

BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a manus...

BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the presentation of pre...

2024-01-08 08:31:12 ET More on Pre-market losers & stocks. Dada Nexus Rides Closer To JD.com's Orbit With Management Shakeup Dada Nexus Limited (DADA) Q3 2023 Earnings Call Transcript Dada Nexus: Lack Of Catalysts Notwithstanding, Appealing Valuations Nxu...

BELTSVILLE, Md., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a ma...